左乙拉西坦添加治疗难治性癫癎的临床观察

Observation of Levetiracetam Add-on Therapy of Refractory Epilepsy

目的:观察左乙拉西坦(LEV)添加治疗难治性癫癎的临床疗效和安全性。方法:对32例难治性癫癎患者进行LEV添加治疗的开放性自身对照研究,观察疗效及不良反应3～12个月。结果:LEV添加治疗3月时总有效率达62.5%,无发作比例为18.75%,与基线比较有显著差异(P<0.001),4～12月疗效与近期相仿。特发性癫癎和症状性癫癎总有效率无统计学差异。1年保留率为66.67%。3例出现体重增加、性格改变等不良反应,停药后消失。结论:LEV添加治疗难治性癫癎有良好疗效,且不良反应轻,保留率高。

Objective： To evaluate the efficacy and safety of levetiracetam （LEV） as add-on therapy in the patients with refractory seizures. Methods： In this open add-on trial,LEV was applied additionally to the treatment of 32 patients with refractory epilepsy. The LEV treatment lasted for 3 to 12 months and the efficacy and side effects were assessed. Results： With three months＇ treatment, the effectiveness ratio （seizure frequency reduction ≥50% ） was 62.50% ,and seizure-free was observed in 6 （18. 75%）patients. LEV produced a significant difference when compared with the pre-LEV period （3 months baseline） （P〈0. 001）. No significant overall clinical efficacy was found between patients with idiopathic epilepsy and those with symptomatic epilepsy after LEV treatment. The efficacy continued for 1 years in 66.67% patients. Three patients showed side effects such as weight increase and personality change that had disappeared after drug withdrawal. Conclusion： LEV is an effective antiepileptic drug for different seizure types.